ORIC Pharmaceuticals to Host ASH Conference Call with Key Opinion Leader to Discuss Potential of ORIC-533 in Multiple Myeloma
ORIC Pharmaceuticals, focused on therapies for cancer resistance, is hosting a conference call on December 13, 2021, at 5:30 p.m. ET to discuss their CD73 inhibitor for multiple myeloma. Senior author Dr. Kenneth Anderson will highlight new ex vivo data presented at the ASH Annual Meeting, showcasing how CD73 inhibition combats immune suppression and boosts antitumor activity. The ASH presentation occurs on December 12, 2021. This event aims to provide insights into the clinical potential of ORIC-533, a molecule targeting key resistance pathways in cancer.
- None.
- None.
Call to discuss poster presentation on ORIC CD73 inhibitor in human ex vivo multiple myeloma systems presented at the American Society of Hematology (ASH) Annual Meeting
Senior author Dr. Kenneth Anderson to discuss beneficial effects of ORIC CD73 inhibitor on restoring human antitumor immunity in multiple myeloma
Webcast event scheduled for Monday, December 13, 2021, at 5:30 p.m. ET
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will host a conference call and webcast to discuss their CD73 inhibitor program in multiple myeloma. On the call, management will be joined by Kenneth C. Anderson, M.D., Kraft Family Professor of Medicine at Harvard Medical School and Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, who will share his perspectives on CD73 inhibition and its promise in overcoming immune suppression in multiple myeloma.
Specifically, the call will focus on new ex vivo data from patients with multiple myeloma being presented at the American Society of Hematology (ASH) Annual Meeting, on the role of adenosine in immunosuppression, and on the ability of an ORIC CD73 inhibitor to restore antitumor immune activity as a single agent.
Details of the ASH poster presentation are as follows:
| Title: | CD73 inhibition overcomes immunosuppression and triggers autologous T-cell mediated multiple myeloma cell lysis in the bone marrow milieu | |
| Abstract #: | 2675 | |
| Date & Time: | Sunday, December 12, 2021, 6:00 - 8:00 pm ET | |
| Session: | 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational |
KOL Webcast and Conference Call Details
ORIC will host a conference call and webcast, Monday, December 13, 2021, at 5:30 p.m. ET. To participate in the conference call, please dial (833) 651-0991 (domestic) or (918) 922-6080 (international) and refer to conference ID 7989199. A live webcast and audio archive of the conference call will be available through the investor section of the company’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials in combination with (1) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors and (2) Xtandi (enzalutamide) in metastatic prostate cancer. ORIC’s other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers. Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on Twitter or LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the role of adenosine in immune suppression; the ability of CD73 inhibition to overcome immune suppression in multiple myeloma; the ability of a single agent CD73 inhibitor to restore antitumor activity; the clinical development of ORIC-533 in multiple myeloma; and the potential benefits of ORIC-533 or the company’s other product candidates. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC-101, ORIC-533, ORIC-944, ORIC-114 or any other product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of the COVID-19 pandemic on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license agreements; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 8, 2021, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Investor Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
FAQ
What is ORIC Pharmaceuticals discussing in their December 13, 2021 conference call?
Who is the senior author discussing the CD73 inhibitor at the ORIC conference call?
When is the ASH Annual Meeting presentation about ORIC's CD73 inhibitor scheduled?
What is the purpose of ORIC's CD73 inhibitor in multiple myeloma?
How can I access the ORIC Pharmaceuticals conference call on December 13, 2021?
